PIM3

Serine/threonine-protein kinase pim-3

107,503 patent compounds predicted against PIM3, 61,435 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL319071	0.64	20/20
SCHEMBL319029	0.63	20/20
SCHEMBL319072	0.60	20/20
SCHEMBL319325	0.57	20/20
SCHEMBL319581	0.56	20/20
SCHEMBL319019	0.56	20/20
SCHEMBL319494	0.55	20/20
SCHEMBL318980	0.54	20/20
SCHEMBL319635	0.54	20/20
SCHEMBL319834	0.54	20/20
SCHEMBL319256	0.53	20/20
SCHEMBL319399	0.53	20/20
SCHEMBL319793	0.53	20/20
SCHEMBL320006	0.53	20/20
SCHEMBL319655	0.51	20/20
SCHEMBL318751	0.50	20/20
SCHEMBL319394	0.59	19/20
SCHEMBL319025	0.58	19/20
SCHEMBL319198	0.58	19/20
SCHEMBL319404	0.55	19/20

Germline variants in PIM3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PIM3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PIM3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma	PHASE2/PHASE3	COMPLETED
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma	PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer	PHASE2	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Apatinib as Second-line Treatment of Advanced Pancreatic Cancer	PHASE2	UNKNOWN
A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects	PHASE1	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer	PHASE1	ACTIVE_NOT_RECRUITING
A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects	PHASE1	COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)	PHASE1	COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Evaluation of Hypoxia in Primary Melanoma	nan	RECRUITING
Immune Interactions in Severe Asthma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PIM3 binder may also engage these)

Protein	Name	Similarity
P58750	—	1.000	P58750 →
O70444	—	1.000	O70444 →
Q9PU85	—	0.989	Q9PU85 →
P26794	—	0.986	P26794 →
P06803	—	0.983	P06803 →
Q91822	—	0.983	Q91822 →
Q95LJ0	—	0.979	Q95LJ0 →
O88764	—	0.977	O88764 →
Q5RCY1	—	0.977	Q5RCY1 →
Q63285	—	0.976	Q63285 →
Q9R011	—	0.976	Q9R011 →
P55203	—	0.976	P55203 →
ULK3	Serine/threonine-protein kinase ULK3	0.975	landscape →
Q62070	—	0.975	Q62070 →
Q6ERS4	—	0.975	Q6ERS4 →
P17105	—	0.975	P17105 →
Q9N0P9	—	0.974	Q9N0P9 →
P52785	—	0.974	P52785 →
EPHB4	Ephrin type-B receptor 4	0.974	landscape →
P63319	—	0.974	P63319 →
P63318	—	0.974	P63318 →
Q4R4U2	—	0.973	Q4R4U2 →
D3ZHP7	—	0.973	D3ZHP7 →
PRKCG	Protein kinase C gamma type	0.973	landscape →
PIM1	Serine/threonine-protein kinase pim-1	0.972	landscape →
Q7XIW5	—	0.972	Q7XIW5 →
O09127	—	0.972	O09127 →
P70218	—	0.971	P70218 →
RPS6KA4	Ribosomal protein S6 kinase alpha-4	0.971	landscape →
Q9Z2B9	—	0.971	Q9Z2B9 →